Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/05/09 18:22:14」(JST)

wiki en

Tositumomab is a drug for the treatment of follicular lymphoma. It is an IgG2a anti-CD20 monoclonal antibody derived from immortalized mouse cells.

Tositumomab is applied in a sequential infusion followed by iodine (¹³¹I) tositumomab, which is the same antibody covalently bound to the radionuclide iodine-131 (¹³¹I).^[1] ¹³¹I emits both beta and gamma radiation and decays with a half-life of 8 days.

Clinical trials have established the efficacy of the tositumomab/iodine (¹³¹I) tositumomab regimen in patients with relapsed or chemotherapy/rituxan refractory follicular lymphoma.

This drug combination is manufactured by Corixa (now GlaxoSmithKline). It sells in the U.S. under the trade name Bexxar.

Bexxar was developed by Dr. Mark Kaminski and Dr. Richard Wahl.

There is some evidence that it may cause a smaller decrease in platelet counts than ibritumomab tiuxetan does.^[2]

References [edit]

^ Bexxar Prescribing Information
^ Jacene HA, Filice R, Kasecamp W, Wahl RL (2007). "Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice". J. Nucl. Med. 48 (11): 1767–76. doi:10.2967/jnumed.107.043489. PMID 17942813.

http://www.med.umich.edu/medschool/faculty/facultyawards/2005/kaminski.htm

External links [edit]

Bexxar regimen entry in the public domain NCI Dictionary of Cancer Terms

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 生物学的製剤を用いた癌治療の神経学的合併症 neurologic complications of cancer treatment with biologic agents
2. 再発性または難治性の濾胞性リンパ腫の治療 treatment of relapsed or refractory follicular lymphoma
3. 造血細胞移植のための前処置療法 preparative regimens for hematopoietic cell transplantation
4. 再発性または難治性のびまん性大細胞型B細胞リンパ腫の治療 treatment of relapsed or refractory diffuse large b cell lymphoma
5. 進行期（III/IV）濾胞性リンパ腫の初期治療 initial treatment of advanced stage iii iv follicular lymphoma

English Journal

Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.

Kelly JL1, Salles G1, Goldman B1, Fisher RI1, Brice P1, Press O1, Casasnovas O1, Maloney DG1, Soubeyran P1, Rimsza L1, Haioun C1, Xerri L1, LeBlanc M1, Tilly H1, Friedberg JW2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.J Clin Oncol.2015 May 1;33(13):1482-90. doi: 10.1200/JCO.2014.57.5092. Epub 2015 Mar 30.
PURPOSE: Recent literature reports a potential association between high vitamin D and improved lymphoma prognosis. We evaluated the impact of pretreatment vitamin D on follicular lymphoma (FL) outcome.PATIENTS AND METHODS: SWOG participants were previously untreated patients with FL enrolled onto SW
PMID 25823738

Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab.

Quackenbush RC1, Horner TJ, Williams VC, Giampietro P, Lin TS.
Leukemia & lymphoma.Leuk Lymphoma.2015 Mar;56(3):779-81. doi: 10.3109/10428194.2014.927461. Epub 2014 Jul 23.
PMID 24898665

Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain.

Vaughan AT1, Chan CH1, Klein C2, Glennie MJ1, Beers SA1, Cragg MS3.
The Journal of biological chemistry.J Biol Chem.2015 Feb 27;290(9):5424-37. doi: 10.1074/jbc.M114.593806. Epub 2015 Jan 7.
Type I anti-CD20 mAb such as rituximab and ofatumumab engage with the inhibitory FcγR, FcγRIIb on the surface of B cells, resulting in immunoreceptor tyrosine-based inhibitory motif (ITIM) phosphorylation. Internalization of the CD20·mAb·FcγRIIb complex follows, the rate of which correlates wit
PMID 25568316

Japanese Journal

Radioimmunotherapy for Non-Hodgkin Lymphoma : Historical Perspective and Current Status

EMMANOUILIDES Christos
Journal of clinical and experimental hematopathology 47(2), 43-60, 2007-11-01
… A similar anti-CD20 radiotherapeutic compound, <SUP>131</SUP>I-tositumomab, was subsequently approved in the USA. …
NAID 10019969918

Radioimmunotherapy(RIT)によるB細胞性リンパ腫治療の展望--Ibritumomab tiuxetan(Zevalin)とtositumomab(Bexxar) (第1土曜特集造血器腫瘍の分子標的療法) -- (期待される分子標的療法とその臨床効果)

小椋美知則
医学のあゆみ 220(9), 741-749, 2007-03-03
NAID 40015287594

High-dose [^<131>I] tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma

GOPAL AK
J Clin Oncol 25, 1396-1402, 2007
NAID 30025931851

Related Pictures

★リンクテーブル★

リンク元	「mab」「トシツモマブ」

「mab」

Tositumomab ^?
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	CD20
Clinical data
Trade names	Bexxar
AHFS/Drugs.com	monograph
MedlinePlus	a609013
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	192391-48-3
ATC code	V10XA53 (sequential regimen with 131I form)
DrugBank	DB00081
UNII	0343IGH41U
KEGG	D08622
ChEMBL	CHEMBL1201604
Chemical data
Formula	C6416H9874N1688O1987S44
Mol. mass	143859.7 g/mol
(what is this?) (verify);